Eligible ages
Adults 18-75
Compensation
Available for time and travel
Who is eligible
• Are between 18 and 75 years of age • Have been taking brand name, injectable semaglutide (Ozempic) for at least 3 months • Had a documented BMI of 30 kg/m² or higher before starting your GLP-1, or BMI of 27 kg/m² with one weight-related comorbidity like hypertension, high cholesterol, cardiovascular disease or obstructive sleep apnea • Have reduced at least 10% of your body weight since you’ve started taking Ozempic • Are willing to discontinue use of Ozempic during the study Additional criteria may apply. A full list of study criteria will be reviewed with you by our team.
What's involved
Qualified participants may receive: • Access to a new investigational medicine • Study-related care at no cost • Compensation may be available for time, travel, and other expenses • The opportunity to help advance potential new options for reducing body weight Participation is voluntary, and health insurance is not required.
Where this study is run
ALSA Research – Manhattan
425 5th Avenue, 6th Floor, Unit 602, New York, NY 10016